We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medifast (MED) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
Medifast (MED - Free Report) closed the most recent trading day at $131.81, moving +0.02% from the previous trading session. The stock lagged the S&P 500's daily gain of 1.09%. Elsewhere, the Dow gained 0.84%, while the tech-heavy Nasdaq added 1.42%.
Heading into today, shares of the weight-loss company had gained 0.53% over the past month, lagging the Consumer Staples sector's gain of 1.49% and the S&P 500's gain of 1.18% in that time.
Investors will be hoping for strength from MED as it approaches its next earnings release. The company is expected to report EPS of $1.52, up 50.5% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $151.70 million, up 53.85% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $6.52 per share and revenue of $709.20 million, which would represent changes of +41.13% and +41.56%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for MED. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 11.45% higher. MED is holding a Zacks Rank of #1 (Strong Buy) right now.
Looking at its valuation, MED is holding a Forward P/E ratio of 20.21. This represents a premium compared to its industry's average Forward P/E of 17.53.
Investors should also note that MED has a PEG ratio of 1.01 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. MED's industry had an average PEG ratio of 2.2 as of yesterday's close.
The Food - Miscellaneous industry is part of the Consumer Staples sector. This group has a Zacks Industry Rank of 100, putting it in the top 40% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MED in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Medifast (MED) Gains But Lags Market: What You Should Know
Medifast (MED - Free Report) closed the most recent trading day at $131.81, moving +0.02% from the previous trading session. The stock lagged the S&P 500's daily gain of 1.09%. Elsewhere, the Dow gained 0.84%, while the tech-heavy Nasdaq added 1.42%.
Heading into today, shares of the weight-loss company had gained 0.53% over the past month, lagging the Consumer Staples sector's gain of 1.49% and the S&P 500's gain of 1.18% in that time.
Investors will be hoping for strength from MED as it approaches its next earnings release. The company is expected to report EPS of $1.52, up 50.5% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $151.70 million, up 53.85% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $6.52 per share and revenue of $709.20 million, which would represent changes of +41.13% and +41.56%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for MED. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 11.45% higher. MED is holding a Zacks Rank of #1 (Strong Buy) right now.
Looking at its valuation, MED is holding a Forward P/E ratio of 20.21. This represents a premium compared to its industry's average Forward P/E of 17.53.
Investors should also note that MED has a PEG ratio of 1.01 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. MED's industry had an average PEG ratio of 2.2 as of yesterday's close.
The Food - Miscellaneous industry is part of the Consumer Staples sector. This group has a Zacks Industry Rank of 100, putting it in the top 40% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MED in the coming trading sessions, be sure to utilize Zacks.com.